This outcome highlights the specificity of KS18 for Mcl-1 and strengthens its therapeutic promise in tumors that are critically reliant on Mcl-1 for survival, including MM and bortezomib-resistant malignancies. The gene discussed is MCL1; the disease is Miyoshi myopathy.